Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by PET remain limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in newly diagnosed PMBL patients and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 cycles. ctDNA and tumor biopsy were analyzed by high-depth, error-corrected sequencing (limit of detection ~10⁻³). Associations between MRD, PET response and progression-free survival (PFS) were evaluated. Among 84 patients, baseline ctDNA was detected in 98%. After four cycles of treatment with R-CHOP14 or R-ACVBP, 87.7% had undetectable MRD. Persistence of MRD after four cycles of therapy was associated with shorter PFS (HR = 78.1 95% CI: 9.5-641.8). The 1-year PFS was 98.4% 95.4-100 for patients with undetectable MRD4 vs. 33.3% 13.2-84 for patients with detectable MRD4 (p<10⁻⁴). MRD4 showed a higher positive predictive value (89% vs. 50%) for disease progression than PET4, maintaining a similar negative predictive value (100% vs. 93%). In multivariate analysis, only PET4(-)/MRD4(-) remained associated with PFS (adjusted HR = 0.07 95% CI: 0.01-0.90). Plasma ctDNA represents a highly abundant source of genetic markers for tumor fingerprinting and disease monitoring. MRD detection following frontline therapy strongly complements PET response criteria in predicting outcome. These findings support the use of ctDNA monitoring as a valuable tool for future risk-adapted strategies in PMBL. NCT04980222.
Camus et al. (Tue,) studied this question.